Abstract. The CD4 + CD25 high regulatory T (Treg) cells have been demonstrated to negatively modulate anti-tumor immune responses in cancer patients. In this study, effects of low dose anti-CD25 antibody (Ab) to attenuate Treg cells were investigated in cancer patients in vitro and in vivo. Peripheral blood mononuclear cells (PBMCs) from cancer patients were cultivated in vitro in the presence of a highaffinity chimeric anti-CD25 Ab (basiliximab). The CD4 + CD25 high population, interferon-gamma (IFN-Á) production and FOXP3 expression were analyzed using flow cytometry (FCM), enzyme-linked immunosorbent assay and reverse transcriptase-polymerase chain reaction (RT-PCR) analysis, respectively. During in vivo studies, basiliximab was administered intravenously on day 1, followed by AIT using autologous activated lymphocytes on day 8, and the treatment cycle was repeated. Subjective and objective effects were observed, and patients' PBMCs were subjected to FCM and RT-PCR analysis. In vitro analysis revealed that a low concentration of 0.01 μg/ml basiliximab reduced almost all of CD4 + CD25 high cells, but less of the CD4 + CD25 low cells, and augmented IFN-Á production of activated PBMCs. FOXP3 mRNA expression of PBMCs was not affected with or without basiliximab. An in vivo study of 9 metastatic cancer patients (7 colorectal and 2 esophageal) demonstrated no subjective or objective adverse effects, even under repeated administration of basiliximab. The results suggested that low-dose basiliximab can safely be administered repeatedly, and can target CD4 + CD25 high Treg cells whilst relatively preserving CD4 + CD25 low activated T cells. The host conditioning with low-dose basiliximab may augment the efficacy of AIT for cancer using activated autologous lymphocytes.
Introduction
A crucial T cell growth factor, interleukin-2 (IL-2) makes it possible to manipulate and propagate natural killer cells and T lymphocytes to be effector cells with highly cytotoxic activity against a wide spectrum of tumor cell types (1, 2) . The effector cells, known as lymphokine-activated killer (LAK) cells (3), tumor-infiltrating lymphocytes (TILs) (4) , and cytotoxic T lymphocytes (CTLs) sensitized with tumor cells (5) , have been introduced into adoptive immunotherapy (AIT) trials for patients with incurable cancer. However, tumor responses have been limited in renal cell carcinoma, malignant melanoma, and non-Hodgkin lymphoma (6, 7) . Identification of tumor antigen genes (8) and professional antigen presenting cells, dendritic cells (DCs), have provided a precise understanding of antigen presentation and recognition machinery (9) . Although this understanding has enabled researchers to introduce the tumor antigen/DC system into the generation of tumor-specific effector cells, the clinical benefits of AIT using these tumor-specific effector cells alone have remained limited (10) . This failure of AIT may be due, in part, to the escape mechanisms of the tumor from the host immune system, which are known to be present in tumor-bearing hosts (11, 12) . (13, 14) . It has been demonstrated that naturally arising Treg cells express the CD4 + CD25 high phenotype and play an essential role in maintaining immunological self-tolerance, which can contribute not only to the inhibition of the development of autoimmune disease, but also to impeding effective immunosurveillance against autologous tumor cells (14) . The attenuation of Treg cellmediated immunosuppression may therefore evoke effective tumor immunity in otherwise non-responsive hosts (15) (16) (17) (18) (19) . It has been demonstrated that AIT using tumor-antigenspecific lymphocytes under host conditioning with lymphodepleting chemotherapy has brought about enhanced tumor responses in patients with malignant melanoma who had otherwise been resistant to immunotherapy (17) . In that study, a preferential decrease of CD4 + T cells compared to CD8 + T cells by lymphodepleting chemotherapy was demonstrated, suggesting the contribution of such chemotherapy to Treg cell depletion. Dannull et al (18) reported that the direct elimination of CD4 + CD25 high Treg cells using the recombinant IL-2-diphtheria toxin conjugate DAB389IL-2, demonstrating that the DAB389IL-2-mediated elimination of Treg cells followed by vaccination with tumor RNAtransfected DCs significantly improves the stimulation of tumor-specific T cell responses in patients with renal cell cancer when compared with vaccination alone. Moreover, Phan et al (15) and Ribas et al (19) conducted clinical trials using anti-CTLA4 Ab for Treg cell attenuation and demonstrated objective tumor responses as well as unfavorable autoimmune diseases.
In the present study, we focused on the use of anti-CD25 antibody as an alternative to lymphodepleting chemotherapy, recombinant IL-2-toxin conjugate and anti-CTLA4 Ab in order to target CD4 + CD25 high Treg cells. Basiliximab, a human-mouse chimeric antibody specific for human CD25 antigen with high affinity, has been introduced into clinics to resolve acute rejection reactions in recipients of organ transplantation, where CD25 + effector T cells that are specific for allogeneic antigens play a central role (20, 21 
Materials and methods
Collection and activation of lymphocytes. Heparinized venous blood was collected from cancer patients after sufficient informed consent was obtained, and peripheral blood mononuclear cells (PBMCs) were separated by standard density centrifugation. For in vitro experiments, PBMCs were cultured in RPMI-1640 medium containing 100 U/ml IL-2 (Sionogi Pharmaceutical Company, Osaka, Japan) plus 1 μM zoledronic acid (Novartis Pharmaceutical Company Tokyo, Japan) at 37˚C for 7-14 days in the presence or absence of human-mouse chimeric anti-CD25 antibody, basiliximab (Novartis Pharmaceutical Company). Activated lymphocytes and culture supernatants were subjected to cytotoxicity assay and IFN-Á assay. For AIT, PBMCs were stimulated with peptide-pulsed autologous dendritic cells and further expanded with an IL-2/anti-CD3 antibody culture system in RPMI-1640 medium supplemented with 2% heat-inactivated autologous plasma, as previously described (10) .
Flow cytometry. PBMCs were stained with 10 μg/ml monoclonal antibodies at 4˚C for 30 min, washed, and analyzed using FACScalibur. The antibodies used were anti-CD3, -CD4, -CD8, -CD25, -CD56, and -Á‰T cell receptor (Becton Dickinson, Mountain View, CA). Data acquisition was stopped at 100,000 events and positive cell populations were analyzed using the attached program after being gated on CD3 + T-cells (22) . The percentage of the reduction of CD4 + CD25 high and CD4 + CD25 low cells by basiliximab was calculated using the following formula: percent reduction = (1-positive cells after administration/positive cells on day 0) x100.
Cytotoxicity assay. The cytotoxic activity of activated lymphocytes was determined by a standard 51 Cr-releasing assay. The target cells, esophageal cancer cell lines TE12 and TE13 (23) , were labeled with 51 Cr for 2 h and admixed with effector lymphocytes in 96-well round-bottomed microtiter plates in triplicate at effector-to-target (E/T) ratios of 10 and 20 in a volume of 200 μl. After overnight incubation, the radioactivity of the supernatants was measured using an auto-gamma scintillation counter (Packard, USA). Spontaneous release was determined in wells containing the target cells alone, and maximum release was obtained by adding 100 μl of 1% Triton X-100 solution over the target cells instead of the effector cells. Cytotoxic activity was calculated from triplicate samples using the following formula: cytotoxic activity (percent) = [experimental release (cpm) -spontaneous release (cpm)] /[maximal release (cpm) -spontaneous release (cpm)] x100.
Interferon-Á measurement. PBMCs were cultured with 100 U/ml IL-2 plus 1 μM zoledronic acid at 37˚C for 7 days in the presence or absence of basiliximab. The culture supernatant was subjected to ELISA specific for IFN-Á (R&D Systems Inc., MN, USA) in triplicate according to the manufacturer's instructions.
RT-PCR analysis. Total RNA was extracted from the 5x10 5 cells of PBMCs using an RNeasy Mini Kit (Qiagen, Hilden, Germany). The prepared total RNA served as the template in first-strand cDNA synthesis using Ready-To-Go™ YouPrime-First-Strand Beads (Amersham Pharmacia Biotech Inc., Piscataway, NJ, USA) with 0.5 μg of Oligo(dT)15 primer (Novagen, Darmstadt, Germany). Aliquots of the cDNA were amplified by PCR using primer pairs specific for FOXP3, T-bet, GATA3, IFN-Á, IL-10 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)(Search-LC GmbH, Heidelberg, Germany) on a LightCycler (Roche Molecular, Mannheim, Germany). The PCR conditions were 95˚C for 10 min for the initial denaturation, followed by 35 cycles of 1 sec at 95˚C, 10 sec at 60˚C, 10 sec at 72˚C, and finally a melting program (60-95˚C) to confirm the correct melting temperature of the product. All clinical samples from patients , and all subjects provided their written informed consent to participate. The patients received intravenous administration of basiliximab (0.01 or 0.005 mg/kg) in 100 ml saline for 20 min on day 0, and autologous activated lymphocytes (1-5 x 10 9 ) in 100 ml saline containing 100,000 U/ml IL-2 for 20 min on day 7. The following treatment cycle proceeded on day 14 and cycles were repeated every 2 weeks for 3 cycles. Adverse effects and tumor responses were carefully evaluated after each treatment cycle. Toxicity was assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. All patients were monitored clinically using imaging analysis such as computed tomographic examination, and clinical efficacy was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) (26) . Hemato-chemistry examination and immunological analysis including flow cytometry and reverse transcriptasepolymerase chain reaction (RT-PCR) analyses were performed every week.
Statistical analysis. Statistical analysis was conducted by paired and unpaired Student's t-tests using StatView software (Version 5) on a Macintosh computer. All values are presented as a mean ± standard deviation, and p<0.05 was defined as statistically significant.
Results

Targeting of CD4 + CD25 high cells by basiliximab in vitro.
Prior to the present clinical study, in vitro investigation was carried out in order to estimate an appropriate starting dose of basiliximab. Patient's PBMCs were incubated with decreasing concentrations of basiliximab (1, 0.25, 0.06, 0.01, 0.001 μg/ml), followed by flow cytometric analysis for detecting CD3 + CD4 + CD25 high and CD3 + CD4 + CD25 low cells (Table I) We then evaluated FOXP3 mRNA expression of patients' PBMCs, which were cultured in the medium alone for 3 or 7 days in the presence or absence of basiliximab, using RT-PCR analysis. FOXP3 mRNA expression was detectable in all patients examined, and there was no significant difference in the FOXP3 mRNA expression with or without basiliximab (data not shown).
Enhancing effects of basiliximab on IFN-Á production by
PBMCs. PBMCs were activated in vitro in the presence or absence of basiliximab, and IFN-Á production in the supernatant was evaluated (Table II) . The presence of basiliximab affected IFN-Á production of PBMCs, which was reproducibly enhanced with 0.01 μg/ml basiliximab (p<0.01) in 3 of 4 independent experiments examined. Basiliximab concentrations larger than 0.1 μg/ml were not effective and were rather inhibitory to IFN-Á production of PBMCs.
Inhibition of cytotoxic activity of effector cells by basiliximab in vitro.
Cytotoxicity assays were performed to determine whether basiliximab at an effector phase is able to inhibit the cytotoxic activity of effector lymphocytes in vitro (Fig. 1) . Concentrations of 1 and 0.3 μg/ml basiliximab resulted in a significant reduction in the cytotoxic activity of effector lymphocytes against TE12 or TE13 tumor cells, when the basiliximab was added at the effector phase of the cytotoxicity assay. However, ≤0.1 μg/ml basiliximab did not inhibit the cytotoxic activity of effector lymphocytes.
Patient characteristics. Nine consecutive patients (5 males, 4 females; median age, 63 years; age range, 42-72 years) with unresectable metastases were enrolled in the present study (Table III) . Their ECOG performance status scores were 0 (n=2), 1 (n=5), 2 (n=1), and 3 (n=1). The subjects were 7 colorectal and 2 esophageal cancer patients, 2 of whom showed lung metastasis alone and 7 of whom showed multiple metastases, including metastases to the lung, liver, lymph node, pleuroperitoneal, skin and brain. All patients had undergone surgical operations to remove the primary tumor, and 4 patients had undergone additional operations for metastasis. Chemotherapy had been previously performed in all patients, and 2 patients had received radiotherapy. AIT using autologous activated lymphocytes had been introduced for 2 patients. All previous treatments had failed. The total number of transferred cells in the present study ranged from 2x10 9 to 24x10 9 cells.
Adverse events. Adverse events related to the systemic administration of basiliximab followed by AIT were carefully observed in an outpatient clinic; hemato-chemistry examinations were also performed. No adverse events were noted either in subjective symptoms or in objective findings, including gastrointestinal symptoms, body temperature, infusion reactions and allergic reactions. Hemato-chemistry examination also found no adverse events in bone marrow, hepatic, or renal function (data not shown). Representative profiles of 0.01 mg/kg basiliximab administration are shown in Fig. 2 , and changes of the populations are summarized in Table IV . In the present treatment, the first 3 subjects received 0.01 mg/kg basiliximab every 2 weeks, the following 3 subjects received 0.005 mg/kg basiliximab, in addition, and the last 3 subjects received 0.01 mg/kg basiliximab as the initial dose followed by 0.005 mg/kg basiliximab as the repeating dose. When 0.01 mg/kg basiliximab was administered, CD4 + CD25 high cells were almost completely reduced on day 1, showing a 95% decrease; on day 7, an 80% decrease was still maintained; and on day 14, the cells restored to the level of a 21% decrease (Table  IV) 
(5) -----------------------------------------------------------------------------------------------------
PBMCs were stained with fluorescence dye-conjugated CD4 and CD25 Abs in the presence of varied concentrations of basiliximab in vitro, washed, and subjected to flow cytometry. Numbers in parenthesis indicate % down-modulation of cell population by basiliximab. basiliximab demonstrated, every 14 days, a repeated reduction on day 7 and restoration on day 14 of CD4 + CD25 high and CD4 + CD25 low cells after basiliximab administration, lasting for at least the 42 days of the study period.
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FOXP3 mRNA expression after low-dose basiliximab administration in vivo.
We analyzed the FOXP3 mRNA expression levels prior to and after the administration of basiliximab (Table V) . FOXP3 mRNA expression levels were decreased by basiliximab in 5 patients, and increased in 3 others; no change was seen in 1 subject. There was no significant difference in FOXP3 mRNA expression levels before and after the administration of basiliximab. We also analyzed T-bet and GATA3 mRNA expression during the treatment. There were no significant differences in these expression before and after the administration of basiliximab INTERNATIONAL JOURNAL OF ONCOLOGY 34: 563-572, 2009 Table II . Enhancing effects of basiliximab on IFN-Á production by PBMCs. ---------------------------------------------- 
-------------------------------------------------Experiment Basiliximab IFN-Á production (pg/ml) (μg/ml) -------------------------Stimulation (-) (+) -
------------------------------------------------
PBMCs were cultured with the IL-2-containing medium in the presence of basiliximab indicated. The culture supernatant on day 7 was subjected to ELISA specific for IFN-Á. Significant difference, a p<0.01. Table III . Patients enrolled in the study. Number of transferred lymphocytes (x10 9 ) (Table V) . Moreover, we did not observe any significant differences in IFN-Á and IL-10 mRNA expression before and after the administration of basiliximab (data not shown). of basiliximab (Table V) . No significant changes were observed in the lymphocyte phenotypes on day 7 or 14 after basiliximab administration.
-------------------------------------------------
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Changes of lymphocyte phenotypes with low
Tumor responses.
No definitive objective responses were observed in this study. However, we experienced possible responses strongly related to low-dose basiliximab administration combined with AIT in 2 colorectal cancer patients with lung metastasis who showed reproducible and apparent decreases in tumor marker CEA. A 72-year-old male patient with lung metastasis had been treated with standard chemotherapy based on 5-FU and with AIT, but all previous treatments had failed with increases of CEA. Lowdose basiliximab administration combined with AIT, however, yielded an obvious decrease in CEA immediately following the treatment, with no adverse effects (Fig. 4) .
Discussion
When using anti-CD25 antibody in cancer immunotherapy, only the targeting of CD4 + CD25 high Treg cells while preserving CD4 + CD25 low activated T cells is ideally required. Ko et al (26) have demonstrated in an animal model that the co-administration of anti-CD25 Ab and anti-glucocorticoidinduced tumor necrosis factor-related protein (GITR) Ab, is less effective than anti-GITR treatment alone for tumor treatment by inhibiting Treg cells, because anti-CD25 Ab reduces not only CD4 + CD25 + naturally occurring Treg cells but also CD25 + activated T cells, which include tumorspecific effector CTLs involved in tumor eradication. The dosage of basiliximab currently recommended for treating acute rejection reactions to renal transplants is a high dose (40-60 mg) that results in a long-lasting (more than one month) complete disappearance of all CD25 + cells (20, 21) , suggesting the requirement of modification for basiliximab administration in cancer immunotherapy. Dannull et al (18) have reported effective elimination of Treg cells with the recombinant IL-2-diphtheria toxin conjugate DAB(389)IL-2 in treating patients with renal cell cancer using tumor RNAtransfected DC vaccines, where a low concentration of 5 nM conjugates is optimal. Therefore, we hypothesized that low doses of anti-CD25 antibody might be sufficient to target CD4 + CD25 high Treg cells without reducing CD4 + CD25 low activated T cells, because CD25 high cells express many more CD25 molecules on the cell surface than do CD25 low cells. In our in vitro experiments, we found that a low concentration of basiliximab at ~0.01 μg/ml achieved preferential targeting of CD4 + CD25 high cells while relatively preserving CD4 + CD25 low cells and was effective for IFN-Á production of PBMCs, although there were differences among individuals. This implied the possibility of low-dose basiliximab administration in vivo, and we therefore designed a clinical study in order to determine the optimal dose of basiliximab. The selected initial dose of 0.01 mg/kg, which may produce a serum concentration of ~0.1 μg/ml basiliximab, was calculated based on a pharmacokinetic study of basiliximab, in which a dose of 60 mg gave a serum concentration of 10 μg/ml immediately following administration (21) . As expected, this Table IV . Down-modulation of CD4 + CD25 high cells due to low-dose basiliximab. ---------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- PBMCs were collected prior to and after treatment, and CD4 + CD25 high and CD4 + CD25 low cells were analyzed by flow cytometry. The percentage of reduction from the value prior to treatment was calculated. N.D., not done. Significant difference, a p<0.05. Table V . Changes in FOXP3 expression and lymphocyte phenotypes due to basiliximab administration. 
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PBMCs were collected from 9 subjects prior to and after treatment. FOXP3, T-bet and GATA3 mRNA expression was analyzed by RT-PCR and the copy numbers were calculated and corrected by GAPDH mRNA expression. Lymphocyte phenotypes were analyzed by flow cytometry. To the best of our knowledge, the low-dose antibody treatment has not yet been investigated in humans. In cancer treatment, the recommended doses of anti-CD20 antibody (Rituximab) (28) and anti-Her2 antibody (Trastuzumab) (29) are 375 mg/m 2 and 4 mg/kg, respectively, which are much higher doses than those found to be appropriate in the present study. Anti-CD3 antibody is also used at a high dose (5 mg) to create immunosuppressive circumstances in regulating acute rejection reactions in organ transplantation (30) . In a study in pigs, Lohse et al (31) investigated a low-dose treatment with murine monoclonal antibodies against porcine CD4 and CD8 surface antigens on lymphocytes, demonstrating specific modulation of the peripheral blood T lymphocyte population and providing a novel method of elucidating their functionality in protecting against infectious disease, even though high-dose administration of the antibody has been only partially successful in achieving short-term cell modulation. In the present investigation, the low-dose administration of basiliximab accomplished the desirable decrease of CD4 + CD25 high cells, even though the low dose of 0.01 mg/kg may be excessive for repeated administration because it reduced CD4 + CD25 low cells to an undesirable degree, indicating that the low-dose approach is highly active for modulating the immune system. We believe that it is important to use the lowest active doses of therapeutic antibodies in order to minimize the burden of injected xenogeneic human-murine chimeric protein, and to reduce the high costs associated with antibody treatment (31) . Moreover, the subjective symptoms or the objective findings, including the hemato-chemistry examinations, showed no adverse effects, indicating the safety of the lowdose administration of basiliximab in combination with AIT. The lymphocyte phenotypes, which were identified using flow cytometry, and the other regulatory T cell populations of T helper type (Th)-1 and Th-2, which were detected by the expression of IFN-Á and T-bet (32) , and IL-10 and GATA3 mRNA (33), respectively, were not affected in this study. These biological effects of the low-dose basiliximab administration remained to be ensured in future clinical trials.
The optimal timing for the addition of anti-tumor immunotherapy to the conditioning regimen using low-dose basiliximab treatment is an important issue, which remains to be resolved. Kudo-Saito et al (34) have addressed this question by examining tumor-bearing mouse models treated with recombinant vaccinia virus vaccine consisting of tumor antigen, B7-1, ICAM-1 and LFA-3 genes, and have demonstrated that vaccine-induced T-cell immune responses can be optimally augmented when anti-CD25 antibody is administered at the same time as vaccination; this apparently indicates that the administration of anti-CD25 Ab at the same time as vaccination does not have an inhibitory effect on subsequently activated T-cell responses. This may be the case in an active immunotherapy protocol, which may require Treg cell targeting by anti-CD25 antibody at the time of vaccination in order to effectively trigger the induction phase of effector cell generation in vivo. However, our case of the AIT protocol using autologous effector lymphocytes activated ex vivo does require Treg cell targeting by anti-CD25 Ab at the effector phase in vivo. When administered at the same time, anti-CD25 Ab directly inhibits the cytotoxic activity of the adoptively transferred effector lymphocytes. The present in vitro experiments showed that the cytotoxic activity of activated effector cells was inhibited at doses of basiliximab of >0.1 μg/ml. Therefore, we added AIT on day 7 after low-dose basiliximab administration, when the basiliximab concentration decreases to <0.1 μg/ml in serum (21) , and just before the CD4 + CD25 high Treg cells targeted by basiliximab begin to recover.
It is useful to know whether Treg cells are physically depleted or functionally modulated by basiliximab treatment. In the present study, FOXP3 mRNA expression was not definitively decreased after basiliximab administration. There is some discussion in the literature suggesting that a targeted population of CD4 + CD25 high cells in flow cytometric analysis after basiliximab administration does not indicate the physical depletion of the cell numbers but rather indicates only the masking of the CD25 high cells escaping detection by flow cytometry using the second anti-CD25 Ab (35) . Moreover, Game et al (36) (38) have demonstrated an exacerbation of autoimmune encephalomyelitis by the administration of anti-CD25 Ab in an animal model, showing, in those mice, a decrease in the CD25 high cell population but not in foxp3 + cells, which suggests that the injection of anti-CD25 Ab results in the functional inactivation, but not physical depletion, of Treg cells; these results are very similar to our own. It has also been reported that CD25 molecules are functionally essential for Treg cells, and that the interruption of the IL-2/IL-2R signaling pathway with anti-CD25 Ab blocks Treg function potentially through alteration in the expression of the glucocorticoid-induced TNFR-family gene (39) . Collectively, these results suggest that the basiliximab treatment in the present study may achieve down-modulation of Treg cell function, but not Treg cell depletion. This issue will be resolved by further functional analyses for Treg cell activity (currently in progress). We were encouraged by the possible, but not yet definitive, clinical responses in this study. The arrest of tumor growth with an obvious decrease in serum tumor markers was observed in 2 of 9 patients enrolled, in whom AIT without basiliximab had failed. A phase II study is thus warranted to ensure the efficacy of AIT using autologous activated lymphocytes in combination with the conditioning treatment of low-dose basiliximab for treating patients with metastatic cancer.
